Junshi Biosciences(688180) 搜狐财经·2025-04-03 19:35Core Viewpoint - The company, Junshi Biosciences, reported significant revenue growth and a reduction in net losses for the fiscal year 2024, indicating improved operational efficiency and potential for future profitability [2][5]. Group 1: Financial Performance - For the fiscal year 2024, Junshi Biosciences achieved a revenue of 1.948 billion yuan, representing a year-on-year increase of 29.67% [2][5]. - The net loss attributable to shareholders narrowed to 1.2809264 billion yuan, compared to a loss of 2.2834319 billion yuan in the previous year [2][5]. - The company has not yet achieved profitability and continues to face cumulative unabsorbed losses, with future profitability dependent on the progress and sales of its pipeline drugs [2]. Group 2: Commercialization and Product Development - The improvement in sales performance is attributed to enhanced efficiency of the commercialization team and the approval of additional indications for the drug Toripalimab, which has been included in the national medical insurance catalog [2]. - The company has four commercially available drugs, and the report indicates growth in drug sales revenue and enhanced self-sustaining capabilities [2]. - Several pipeline products are nearing commercialization, with accelerated development and completion of clinical trials for approved products in more indications, which is expected to improve the company's financial situation [2]. Group 3: Fundraising Activities - The net amount raised from the initial public offering (IPO) was 4.4969783 billion yuan, while the net amount raised from the issuance of shares to specific investors was 3.7448028 billion yuan [2][5]. - The shares were issued at a price of 53.95 yuan per share, with a total fundraising amount of 3.7765 billion yuan [3].